NCT02946632View on ClinicalTrials.gov

Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes

PHASE3UnknownINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Diabetes Mellitus, Type II
Interventions
DRUG

triple combination therapy

Xigduo (metformin 1000mg + dapagliflozin 10mg) saxagliptin 5mg

DRUG

Stepwise add-on therapy

metformin -\> glimepirde -\> sitagliptin

Trial Locations (1)

Unknown

Korea University Anam Hospital, Seoul

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Korea University Anam Hospital

OTHER